Neonates and infants undergoing cardiac surgery with cardiopulmonary bypass are exposed to multiple blood products from different donors. The volume of the bypass circuit is often as large as the patient’s total blood volume and asanguineous bypass primes are unusual. As a result, blood products are required for the cardiopulmonary bypass prime and are often used to treat the postbypass dilutional coagulopathy. We review clot formation and strength, cardiopulmonary bypass prime considerations, assessment of postbypass coagulopathy, component therapy use, ultrafiltration techniques, and use of antifibrinolytic medications. A combined approach including techniques to minimize the prime volume, utilization of ultrafiltration, administration of antifibrinolytics during surgery, and the proper treatment of the dilutional coagulopathy can limit the transfusion requirements.
BanburyMKBrizzioMERajeswaranJLytleBWBlackstoneEH.Transfusion increases the risk of postoperative infection after cardiovascular surgery. J Am Coll Surg. 2006; 202(1):131–138.
2.
SzekelyACserepZSapiE. Risks and predictors of blood transfusion in pediatric patients undergoing open heart operations. Ann Thorac Surg. 2009;87(1):187–197.
3.
FransenEMaessenJDentenerMSendenNBuurmanW.Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999;116(5):1233–1239.
4.
HickeyEKaramlouTYouJUngerleiderRM.Effects of circuit miniaturization in reducing inflammatory response to infant cardiopulmonary bypass by elimination of allogeneic blood products. Ann Thorac Surg. 2006;81(6):S2367–S2372.
5.
HoffmanMMonroeDM3rd.A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958–965.
6.
HockinMFJonesKCEverseSJMannKG.A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002;277(21):18322–18333.
7.
BrummelKEParadisSGButenasSMannKG.Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002;100(1):148–152.
8.
CoughlinSR.Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258–264.
9.
NieuwlandRBerckmansRJRotteveel-EijkmanRC. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation. 1997;96(10):3534–3541.
10.
NielsenVGGurleyWQJr. Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg. 2004;99(1):120–123.
11.
LangTJohanningKMetzlerH. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg. 2009;108(3):751–758.
12.
WagnerCLMascelliMANeblockDSWeismanHFCollerBSJordanRE.Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88(3):907–914.
13.
MillerBETosoneSRGuzzettaNAMillerJLBrosiusKK.Fibrinogen in children undergoing cardiac surgery: is it effective?Anesth Analg. 2004;99(5):1341–1346.table of contents.
14.
LorandL.Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:291–311.
15.
ChandlerWLPatelMAGravelleL. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2001;12(2):101–108.
16.
GolabHDTakkenbergJJvan Gerner-WeelinkGL. Effects of cardiopulmonary bypass circuit reduction and residual volume salvage on allogeneic transfusion requirements in infants undergoing cardiac surgery. Interact Cardiovasc Thorac Surg. 2007;6(3):335–339.
17.
KosterAHueblerMBoettcherWRedlinMBergerFHetzerR.A new miniaturized cardiopulmonary bypass system reduces transfusion requirements during neonatal cardiac surgery: initial experience in 13 consecutive patients. J Thorac Cardiovasc Surg. 2009;137(6):1565–1568.
18.
GolabHDBogersJJ.Small, smaller, smallest. Steps towards bloodless neonatal and infant cardiopulmonary bypass. Perfusion. 2009;24(4):239–242.
19.
FukumuraFKadoHImotoY. Usefulness of low-priming-volume cardiopulmonary bypass circuits and dilutional ultrafiltration in neonatal open-heart surgery. J Artif Organs. 2004;7(1):9–12.
20.
AndoMTakahashiYSuzukiN.Open heart surgery for small children without homologous blood transfusion by using remote pump head system. Ann Thorac Surg. 2004;78(5):1717–1722.
21.
DiNardoJA.Physiology and techniques of extracorporeal circulation in the pediatric patient. In: LakeCBookerP (Eds.), Pediatric Cardiac Anesthesia. 4th ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2005;228–252.
22.
NakanishiKShichijoTShinkawaY. Usefulness of vacuum-assisted cardiopulmonary bypass circuit for pediatric open-heart surgery in reducing homologous blood transfusion. Eur J Cardiothorac Surg. 2001;20(2):233–238.
23.
WypijDJonasRABellingerDC. The effect of hematocrit during hypothermic cardiopulmonary bypass in infant heart surgery: results from the combined Boston hematocrit trials. J Thorac Cardiovasc Surg. 2008;135(2):355–360.
24.
GruenwaldCEMcCrindleBWCrawford-LeanL. Reconstituted fresh whole blood improves clinical outcomes compared with stored component blood therapy for neonates undergoing cardiopulmonary bypass for cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg. 2008;136(6):1442–1449.
25.
HornykewyczSOdegardKCCastroRAZurakowskiDPigulaFDiNardoJA.Hemostatic consequences of a non-fresh or reconstituted whole blood small volume cardiopulmonary bypass prime in neonates and infants. Paediatr Anaesth. 2009; 19(9):854–861.
26.
BolligerDSzlamFAzranMKoyamaKLevyJHMolinaroRJTanakaKA.The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg. 2010;111(3):601–608.
27.
TanakaKAKeyNSLevyJH.Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009;108(5):1433–1446.
28.
RomlinSWåhlanderHBerggrenH. Intraoperative thromboelastometry is associated with reduced transfusion prevalence in pediatric cardiac surgery. Anesth Analg. 2011;112(1):30–36.
29.
RoystonDvon KierS.Reduced haemostatic factor transfusion using heparinase- modified thrombelastography during cardiopulmonary bypass. Br J Anaesth. 2001;86(4):575–578.
30.
MillerBEMochizukiTLevyJH. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg. 1997;85(6):1196–1202.
31.
HaasTFriesDVelik-SalchnerCOswaldEInnerhoferP.Fibrinogen in craniosynostosis surgery. Anesth Analg. 2008;106(3):725–731.
32.
Rahe-MeyerNSolomonCWinterhalterM. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg. 2009;138(3):694–702.
33.
DraaismaAMHazekampMGFrankMAnesNSchoofPHHuysmansHA.Modified ultrafiltration after cardiopulmonary bypass in pediatric cardiac surgery. Ann Thorac Surg. 1997;64(4):521–525.
34.
WilliamsGDRamamoorthyCChuL. Modified and conventional ultrafiltration during pediatric cardiac surgery: clinical outcomes compared. J Thorac Cardiovasc Surg. 2006;132(6):1291–1298.
35.
FriesenRHCampbellDNClarkeDRTornabeneMA.Modified ultrafiltration attenuates dilutional coagulopathy in pediatric open heart operations. Ann Thorac Surg. 1997;64(6):1787–1789.
36.
OotakiYYamaguchiMOshimaYYoshimuraNOkaS.Effects of modified ultrafiltration on coagulation factors in pediatric cardiac surgery. Surg Today. 2002;32(3):203–206.
37.
WilliamsGDBrattonSLRileyECRamamoorthyC. Efficacy of epsilon-aminocaproic acid in children undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 1999;13(3):304–8.
38.
RaoBHSaxenaNChauhanSBisoiAKVenugopalP. Epsilon aminocaproic acid in paediatric cardiac surgery to reduce postoperative blood loss. Indian J Med Res. 2000;111:57–61.
39.
ChauhanSKumarBARaoBHRaoMSDubeyBSaxenaNVenugopalP. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. Ann Thorac Surg. 2000;70(4):1308–12.
40.
ChauhanSDasSNBisoiAKaleSKiranU. Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. J Cardiothorac Vasc Anesth. 2004;18(2):141–3.
41.
ZonisZSeearMReichertCSettSAllenC. The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. J Thorac Cardiovasc Surg. 1996;111(5):982–7.
42.
ReidRWZimmermanAALaussenPCMayerJEGorlinJBBurrowsFA. The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Anesth Analg. 1997;84(5):990–6.
43.
LevinEWuJDevineDVAlexanderJReichartCSettSSeearM. Hemostatic parameters and platelet activation marker expression in cyanotic and acyanotic pediatric patients undergoing cardiac surgery in the presence of tranexamic acid. Thromb Haemost. 2000;83(1):54–9.
44.
ChauhanSBisoiAModiRGhardePRajeshMR. Tranexamic acid in paediatric cardiac surgery. Indian J Med Res. 2003;118:86–9.
45.
ChauhanSBisoiAKumarNMittalDKaleSKiranUVenugopalP. Dose comparison of tranexamic acid in pediatric cardiac surgery. Asian Cardiovasc Thorac Ann. 2004;12(2):121–4.
46.
BulutcuFSOzbekUPolatBYalcinYKaraciARBayindirO. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?Paediatr Anaesth. 2005;15(1):41–6.
